Nichole Tucker | Authors

Nichole Tucker, MA, is the Senior Editor for Targeted Oncology and host of the Targeted Talks podcast. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.

Articles

GFH009 Demonstrate Early Efficacy in Relapsed/Refractory Lymphoma and AML

June 28, 2022

Article

In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.

Chemotherapy Plus HER-Vaxx Shows Efficacy in HER-2/Neu+, Advanced/Metastatic Gastric or GEJ Cancer

June 28, 2022

Article

Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC

June 27, 2022

Article

In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.

FDA Approves Liso-Cel for Second-Line Treatment of R/R LBCL

June 25, 2022

Article

The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.

Tazemetostat Results Signal the Utility of Biomarker-Driven Therapy for BAP1-Inactivated MPM

June 24, 2022

Article

Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.

FDA Approval Sought for Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer

June 24, 2022

Article

Developers of elacestrant are seeking FDA approval of the agent for the treatment of patients with ER-positive/HER2-negative advanced or metastatic breast cancer.